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M etastatic or advanced urothelial carcinoma (UC) has become a more common disease in 
Japan as the percentage of elderly citizens continues to 
increase.  This carcinoma is life-threatening,  with a 
median survival time of < 6 months without treatment.  
In the efforts to identify an effective treatment for 
advanced UC,  the combination of methotrexate,  vin-
blastine,  doxorubicin,  and cisplatin (MVAC) showed 
modest improvement as a first-line chemotherapy [1].  
In 2000,  the combination of gemcitabine and cisplatin 
(GC) was reported as a newly promising therapy pro-
viding similar survival times and better tolerability 
compared to MVAC [2].  GC and MVAC are the gold 
standard treatments for metastatic or advanced UC as 
first-line chemotherapy with the initial high response 
rate of 50% and the median progression-free survival 
(PFS) and overall survival (OS) of 8 months and 
14 months,  respectively [2 , 3]; however,  most of the 
patients who received these first-line chemotherapies 
relapsed and required additional therapy.  There are as 
yet no standard second-line treatments or salvage ther-
apy for metastatic or advanced UC.
Single-agent taxane or gemcitabine or a combina-
tion of them are commonly used as second-line or sal-
vage therapy for metastatic or advanced UC.  Single-
arm phase II trials reported that single-agent taxane 
therapies resulted in a moderate response rate of 
10-20% and an OS rate of 6-9 months [4 , 5].  Taxane 
showed a more improved OS when used in combina-
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There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC).  Here we inves-
tigated the efficacy and safety of gemcitabine,  cisplatin,  and paclitaxel (GCP) combination chemotherapy as 
salvage chemotherapy for advanced UC.  We retrospectively analyzed the cases of 23 patients with advanced UC 
who showed progression or recurrence after cisplatin-based chemotherapy.  Gemcitabine (1000 mg/m2),  and 
paclitaxel (80 mg/m2) were administered on days 1 and 8.  Cisplatin (70 mg/m2) was administered on day 1.  The 
3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity.  The overall 
response rate was 61% (95%CI,  41-78%).  The median overall survival and progression-free survival times were 
14 months and 5.5 months,  respectively.  Of the already known risk factors of chemotherapy for advanced UC,  
only the performance status was a prognostic factor for OS.  Overall,  16 of the 23 patients (70%) experienced 
grade 3/4 toxicities,  and no fatal adverse events were observed.  GCP therapy was a promising option as sec-
ond-line or salvage therapy for advanced UC.
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tion with other agents compared to its single use [6].  
Although taxane could be a key drug in the future as a 
second-line chemotherapy for metastatic or advanced 
UC,  cisplatin is thought to have some beneficial effect 
on some patients even after the failure of cisplatin- 
based chemotherapy.  As there is no useful biomarker to 
predict cisplatin sensitivity or resistance,  cisplatin 
should be included after first-line chemotherapy con-
sidering its marked effect on urothelial carcinoma.
In light of this background,  we designed the combi-
nation of gemcitabine,  cisplatin,  and paclitaxel (GCP) 
for patients with advanced UC after the failure of a plat-
inum-based regimen.  This is the first study to investi-
gate the efficacy and safety of GCP treatment as a sal-
vage therapy for advanced UC.
Some studies have attempted to identify the prog-
nostic factors in chemotherapy for advanced UC.  The 
most likely potential factors are the Eastern Cooperative 
Oncology Group performance status (ECOG PS),  
hemoglobin (≤ 10 g/dL vs. > 10 g/dL),  albumin (≤ the 
lower limit of normal vs. > the lower limit of normal),  
the presence of liver metastases,  and the time from 
prior chemotherapy (TFPC) (≤ 3 months vs. > 3 months) 
[7 , 8].  We also investigated whether these five factors 
could be prognostic factors in advanced UC patients 
treated with GCP.
Patients and Methods
Study population. A total of 23 patients who 
received the GCP regimen as second-line or third-line 
chemotherapy for advanced or metastatic UC were 
included in this study.  All of the patients showed pro-
gressive disease after prior platinum-based therapy 
(MVAC or GC) in a perioperative or metastatic setting.  
In a perioperative setting,  first-line chemotherapy was 
administered in 2 or 3 cycles as neoadjuvant or adjuvant 
chemotherapy.  Second-line chemotherapy or GCP 
treatment was administered when metastasis or local 
recurrence appeared in the course of follow-up.  GCP 
treatment as third-line chemotherapy was administered 
when progressive disease was shown on radiological 
images in the course of or after second-line chemother-
apy.
In the cases with metastasis,  first-line chemotherapy 
was administered as long as it was observed to be effec-
tive on radiological images.  Second-line chemotherapy 
or GCP treatment was administered when progressive 
disease was shown on radiological images in the course 
of or after first-line chemotherapy.  GCP treatment as 
third-line chemotherapy was administered when pro-
gressive disease was seen on radiological images in the 
course of or after second-line chemotherapy.
Each patient’s UC had to have been proved histolog-
ically prior to the administration of the GCP treatment.  
The GCP treatment was administered between January 
2011 and December 2016 at Hiroshima City’s Hiroshima 
Citizens Hospital,  and we reviewed the patients’ medical 
records retrospectively.  The study protocol was 
approved by the Ethics Committee of Hiroshima 
Citizens Hospital (approval no.  29-29).
Treatment schedule. Gemcitabine and paclitaxel 
were administered at 1000 mg/m2 and 80 mg/m2,  respec-
tively on days 1 and 8.  Cisplatin was administered at 
70 mg/m2 on day 1.  This regimen was continued as long 
as it was effective objectively and the toxicity was toler-
able.  These regimen doses were decreased according to 
the patients’ renal function and the extent of adverse 
events.
Patient evaluation. We obtained the patients’ 
demographic data and treatment details from the med-
ical records.  Age,  gender,  ECOG PS,  the primary site 
of the tumor,  metastatic site(s) of the tumor,  prior 
therapies,  and baseline laboratory data were included in 
the demographic data.  Treatment response,  number of 
cycles,  the date of progression,  and the date of death 
were included in the GCP treatment details.  All treat-
ment-associated toxicity data specifically on hemato-
logic toxicity rates and febrile neutropenia were 
recorded.  Tumor responses were assessed using 
Response Evaluation Criteria in Solid Tumors (RECIST,  
ver.  1.1),  classified as complete response (CR),  partial 
response (PR),  stable disease (SD),  and progressive 
disease (PD).  The best overall response on RECIST was 
recorded as the treatment response.  Toxicity was assessed 
using the U.S.  National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE,  ver.  
3.0).
Statistical analysis. We defined the responders as 
CR + PR.  We defined OS as the time from the start of 
GCP treatment to the date of death,  and PFS was 
defined as the time from the start of GCP treatment to 
the date of objective progression.  The cases of the 
patients who were still alive at the date of the last fol-
low-up were censored.  OS and PFS were estimated by 
the Kaplan-Meier method.  We assessed the variables 
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with potential as prognostic factors (i.e.,  the ECOG PS,  
hemoglobin,  albumin,  the TFPC,  and the presence of 
liver metastasis) for OS and PFS by performing univar-
iate and multivariate analyses with a Cox regression 
model.  All statistical analyses were performed with the 
JMP 10 program (SAS,  Cary,  NC).  Statistical signifi-
cance was defined by a p-value < 0.05.
Results
Patient characteristics. The baseline characteris-
tics of the patients are summarized in Table 1.  Thirteen 
of the 23 patients (57%) had an ECOG PS of ≥ 1.  Five 
patients had liver metastasis,  and visceral metastasis 
were seen in 16 patients.  The GCP regimen was admin-
istered in 21 patients (91%) as second-line chemother-
apy after a GC regimen,  and the other two patients 
(9%) received the GCP regimen as third-line chemo-
therapy after GC and MVAC regimens.  The median 
follow-up period was 12 months (range 3-55 months).
Efficacy. The overall response rate to GCP therapy 
was 61% (Table 2).  All 14 patients of these responders 
showed a PR.  The PR rates in individual metastatic sites 
are presented in Table 3.  The PR rates of the liver 
metastasis and lung metastasis were 80% and 55%,  
respectively.
The median OS and PFS rates were 14.0 months 
(95% confidence interval [CI]: 9-23 months) and 5.5 
months (95%CI 4-7 months),  respectively (Fig. 1).
Treatment administration and toxicity. The 
average number of GCP treatments administered was 
3.5 (range 1-8).  The frequencies of grade 3 or higher 
adverse events are shown in Table 4.  Grade 3/4 toxici-
ties were observed in 70% (n = 16) of the 23 patients,  
and no fatal adverse events were observed.  Grade 3-4 
anemia,  neutropenia,  and thrombocytopenia occurred 
in 21%,  47%,  and 39% of patients,  respectively.  No 
patients had febrile neutropenia.  The major reasons for 
the discontinuation of GCP treatment were progressive 
disease (48%) and the patient’s request for outpatient 
treatment (22%).  The other reasons for discontinuation 
could not be discerned from the medical records.
Association of factors with overall and progres-
sion-free survival. The univariate analyses identified 
only the ECOG PS as significantly associated with OS 
(Table 5).  In the multivariate analyses,  the ECOG PS 
was an independent prognostic factor for OS with the 
hazard ratio of 6.5 (95%CI 1.5-33.7,  p = 0.012).  All of 
the other 4 prognostic factors were not significantly 
associated with OS or PFS.
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Table 1　 Baseline patient characteristics
Characteristics Number of patients (%)
Age
   <70 years 10 (43%)
   ≥70 years 13 (57%)
Gender
   Male 19 (83%)
   Female 4 (17%)
ECOG-PS
0 10 (43%)
1 10 (43%)
   ≥2 3 (14%)
Site of primary tumor
   Bladder 9 (39%)
   Ureter 5 (22%)
   Renal pelvis 9 (39%)
Site of recurrence or metastasis
   Local 4
   Lymphnode 16
   Lung 11
   Liver 5
   Bone 5
   Muscle 2
Prior choemotherapy
   GC 21 (91%)
   GC+MVAC 2 (9%)
Purpose of prior chemotherapy
   Neoadjuvant 8
   Adjuvant 12
   For recurrence or metastasis 7
TFPC
   <3 months 8 (35%)
   ≥3 months 15 (65%)
Table 3　 Rates of partial response in each site of metastasis
Site of metastasis Number Number of PR (%)
Liver 5 4 (80)
Lung 11 6 (55)
Lymphnode 16 6 (38)
Local 4 3 (75)
Muscle 2 1 (50)
Table 2　 Response for GCP
RECIST evaluation Number of patients (%)
CR 0 (0%)
PR 14 (61%)
SD 6 (26%)
PD 3 (13%)
Discussion
In the era of GC treatment as first-line chemother-
apy for advanced UC,  there is no standard treatment as 
a second-line chemotherapy.  Changing agents from 
prior regimens or adding new agents is a basic strategy 
to maintain efficacy in the subsequent therapy.  For 
instance,  the use of the MVAC regimen after progres-
sion or relapse following GC treatment produced a 
response rate of 30%,  with the median PFS and OS rates 
of 5.3 and 10.9 months,  respectively [9].  In our study,  
GC was used as the first-line chemotherapy in 21 (91%) 
patients,  and 61% of the patients showed a PR with the 
median PFS and OS rates of 5.5 and 14 months,  respec-
tively.  Although only paclitaxel was added to the first-
line GC treatment,  the GCP regimen produced a better 
response with more tolerable toxicity than MVAC.
Paclitaxel has been the most commonly used drug 
in second-line or salvage therapy in advanced UC.  The 
combination of paclitaxel and other drugs has been 
confirmed to exert more efficacy in the salvage setting 
[6].  In the several combinations of paclitaxel and other 
drugs,  the combination of gemcitabine and paclitaxel 
(GP) is the most acceptable therapy [10].  Several 
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Table 4　 Laboratory toxicity rates
Grade 3 Grade 4
Number of patients (%) Number of patients (%)
Anemia 5 (21%) 0 (0%)
Leukopenia 9 (39%) 2 (30%)
Neutropenia 4 (17%) 7 (30%)
Febrile neutropenia 0 (0%) 0 (0%)
Thrombocytopenia 3 (13%) 6 (26%)
Hyponatremia 1 (4%) 1 (4%)
Hypokalemia 1 (4%) 0 (0%)
Table 5　 Univariable analyses for association of valiables with overall and progression -free survival
Factor Type HR (95% CI) p value
Overall survival
ECOG PS >0 vs 0 4.4 (1.4︲16.7) 0.009＊
Hemoglobin <10 vs ≥10 1.2 (0.2︲4.3) 0.9
Albumin Below LLN vs normal 2.2 (0.8︲6.5) 0.1
Time from prior chemotherapy <3 vs ≥3 months 1.7 (0.6︲4.3) 0.3
Liver metastasis Yes vs no 0.9 (0.2︲2.8) 0.9
Progression-free survival
ECOG PS >0 vs 0 2.1 (0.8︲5.7) 0.1
Hemoglobin <10 vs ≥10 1.1 (0.2︲3.8) 0.9
Albumin Below LLN vs normal 1.6 (0.6︲4.5) 0.1
Time from prior chemotherapy <3 vs ≥3 months 1.3 (0.5︲3.1) 0.3
Liver metastasis Yes vs no 0.7 (0.2︲2.2) 0.6
Asterisk indicates statistical signiﬁcance (p<0. 05); LLN= lower limit of normal (LLN of Albumin: 4.0 g/dl)
Unit of Hemoglobin: g/dl　Unit of Albmin: g/dl
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Fig. 1　 A,  Overall survival in GCP 
treatment; B,  Progression free sur-
vival in GCP treatment.
phase II trial showed that GP combination therapy can 
provide an objective response rate ranging from 33% 
to 60%,  a median OS rate of 9-14.4 months,  and a 
median PFS of 4-11 months [11-15].  The GCP triplet 
therapy examined in our present study showed almost 
the same efficacy as that of GP combination therapy.  In 
basic research using bladder cancer cell lines,  however,  
the effects of cisplatin could be optimized by combina-
tion with paclitaxel [16].  Some patients are still cispla-
tin-sensitive even after recurrence or relapse following 
a cisplatin-based regimen.
In our prognostic factor analyses,  the TFPC was not 
revealed as a significant independent prognostic factor 
for PFS and OS following GCP treatment,  which sug-
gests that patients can still be sensitive to cisplatin even 
after early recurrence or relapse following a cispla-
tin-based regimen.
As for toxicity,  phase II trials of combination ther-
apy of gemcitabine and paclitaxel showed the following 
percentages: grade 3-4 anemia,  0-28%; neutropenia,  
16-46%; and thrombocytopenia,  0-16%.  Febrile neu-
tropenia ranged from 7% to 16% [11-15].  In our pres-
ent analysis of GCP treatment,  neutropenia and throm-
bocytopenia were observed at relatively high frequencies,  
but they were dealt with in the clinical setting without 
the development of any severe clinical problems.
The limitations of this study were the small number 
of patients (n = 23) and the retrospective design.  
Nevertheless,  the results of our analyses of the patients’ 
GCP treatment suggested that this therapy has good 
efficacy as a salvage treatment for advanced UC.  
Prospective and large cohort studies are needed to 
reveal biomarkers that will identify the maximum 
benefit of GCP treatment.
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